--- title: Life Sciences and Chemistry date: 2022-01-28T10:36:22Z modified: 2026-08-18T12:33:11Z permalink: "https://www.htgf.de/en/life-sciences-and-chemistry/" type: page status: publish excerpt: "" wpid: 95556 language: - English post_translations: - pll_61f1394f454b3 timestamp: 2026-08-18T12:33:11Z tags: - English - pll_61f1394f454b3 --- ## _We invest in people._ # In Life Sciences & Chemistry![](https://www.htgf.de/wp-content/uploads/2025/11/headline-marker-2-high-white-921.webp) . [⌵](#trackrecord) Our _Track Record_ Life Sciences and Chemistry ## > 200 [Ventures](#) ## 56 [Exits](#) ## 7 [Focus sectors](#) > > _“HTGF is very supportive and easy to work with._ > > They foster a collaborative environment and respond very fast to any request.**”** > > > > ![](https://www.htgf.de/wp-content/uploads/2025/02/David-Neale-Arga-Medtech.jpg) **David Neale** > > _Founder and CEO of Argá Medtech_ ## Spotlight _Life Sciences & Chemistry_ 8 of 500 Companies ![](https://www.htgf.de/wp-content/uploads/2022/06/eeden-Series-A-l.-Steffen-Gerlach-r.-Dr.-Tobias-Boernhost.png) 2022 ### EEDEN Recycling ### From textile waste to tomorrow’s resources. to EEDEN [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/eeden.md) ![Argá Medtech](https://www.htgf.de/wp-content/uploads/2021/02/Arga-Medtech_logo.png) 2021 ### Argá Medtech Life Sciences ### Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation to Argá Medtech [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/arga-medtech.md) ![](https://www.htgf.de/wp-content/uploads/2020/07/Management-Team-Tubulis_quadratisch.png) 2020 ### Tubulis Exit Oncology ### Development of enhanced antibody-drug conjugates for improved cancer treatment to Tubulis [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/tubulis.md) ![](https://www.htgf.de/wp-content/uploads/2020/01/Karsten-Lindhardt_quadratisch.png) 2019 ### Biograil Drug Delivery ### Breakthrough technology for the oral delivery of biologics in a standard size capsule to Biograil [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/biograil.md) ![Emergence Therapeutics Logo](https://www.htgf.de/wp-content/uploads/2020/03/LOGO-HORIZEMAIL.png) 2019 ### Emergence Therapeutics Exit Oncology ### Novel antibody drug conjugates to treat high need cancers to Emergence Therapeutics [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/emergence-therapeutics-3.md) ![](https://www.htgf.de/wp-content/uploads/2017/06/logo-cardior-mesh-green-RGB_300dpi-1920x768.png) 2017 ### CARDIOR Exit Cardiology / Cardiovascular ### Pioneer in the development of new therapeutics for heart disease to CARDIOR [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/cardior.md) ![MYR Logo](https://www.htgf.de/wp-content/uploads/2014/09/MYR_Logo2.jpg) 2011 ### MYR Exit Pharmaceuticals ### First-in-class Entry-Inhibitor for the treatment of chronic hepatitis Delta to MYR [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/myr-2.md) ![](https://www.htgf.de/wp-content/uploads/2014/09/c-Lecta_quadratisch.png) 2006 ### c-LEcta Exit Industrial Biotech ### c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either … to c-LEcta [Unternehmen ansehen](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/portfolio/c-lecta-2.md) 3 of 500 Companies [our portfolio](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/page/portfolio.md#h-the-complete-portfolio) ## Tomorrow**’**s market will be different _We invest now_ Pharma, BioTech, R&D Tools and DiagnosticsGermany is one of the global leaders in life science research. We invest in disruptive technologies and visionaries not only to further innovation, but also to actively shape the market. MedTech and Digital HealthSocietal challenges such as demographic change, the shortage of skilled workers or complex diseases demand visionary answers. Together, we transform these into market-relevant solutions. ChemistryHow do we feed a growing world population in the future, how do we counter the effects of climate change? We believe in the answers provided by science – and we know the challenges of lab-to-market startups from our own experience. [submit your pitch deck](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/page/contact.md) ## Success stories _People invest in People_ Last update 4 hours ago ![](https://www.htgf.de/wp-content/themes/htgf/assets/images/HTGF-Mastergradient-40.webp) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/fda-approval-hepcludex.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 26 Mai 2026 ### FDA grants accelerated approval to Hepcludex® — originally developed by HTGF portfolio company MYR GmbH [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 26 Mai 2026 ### FDA grants accelerated approval to Hepcludex® — originally developed by HTGF portfolio company MYR GmbH ![](https://www.htgf.de/wp-content/uploads/2026/04/Dominik-Schumacher_4-3.jpg) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/gilead-to-acquire-htgf-backed-biotech-tubulis.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 April 2026 ### Gilead to Acquire HTGF-Backed Biotech Tubulis for up to $5 Billion [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 April 2026 ### Gilead to Acquire HTGF-Backed Biotech Tubulis for up to $5 Billion ![](https://www.htgf.de/wp-content/themes/htgf/assets/images/HTGF-Mastergradient-40.webp) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/evlabio-raises-e21-million-seed-funding.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 Juli 2025 ### EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease. [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 Juli 2025 ### EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease. ![](https://www.htgf.de/wp-content/uploads/2025/04/eeden-Series-A-l.-Steffen-Gerlach-CEO-Co-Founder-r.-Dr.-Tobias-Boernhost-CTO-Co-Founder.jpg) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/eeden-completion-of-series-a-funding.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 29 April 2025 ### eeden Closes €18M Series A Financing to Scale its Breakthrough Textile Recycling Technology [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 29 April 2025 ### eeden Closes €18M Series A Financing to Scale its Breakthrough Textile Recycling Technology ![](https://www.htgf.de/wp-content/themes/htgf/assets/images/HTGF-Mastergradient-40.webp) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/heparegenix-completes-e21-5-million-financing.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 15 April 2025 ### HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 15 April 2025 ### HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration ![](https://www.htgf.de/wp-content/uploads/2025/04/1-1.jpg) [zum Artikel](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/post/htgf-exit-gme.md) [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 April 2025 ### Successful exit for HTGF: German Medical Engineering joins the Thomas Group [News](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/taxonomy/category/news-en.md) 7 April 2025 ### Successful exit for HTGF: German Medical Engineering joins the Thomas Group ## Science-driven with entrepreneurial spirit _The Life Sciences & Chemistry Team_ ![](https://www.htgf.de/wp-content/uploads/2021/07/Website_2.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-angelika-vlachou.md) ### Dr. Angelika Vlachou Partner ### Dr. Angelika VlachouPartner ![](https://www.htgf.de/wp-content/uploads/2014/10/Bernd-Goergen_Website.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-bernd-goergen-2.md) ### Dr. Bernd Goergen Partner ### Dr. Bernd GoergenPartner ![](https://www.htgf.de/wp-content/uploads/2014/10/HTGF-Marco-Winzer-864x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/marco-winzer-2.md) ### Marco Winzer Partner ### Marco WinzerPartner ![](https://www.htgf.de/wp-content/uploads/2021/04/HTGF-090620261656-2-864x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/nikolaus-raupp.md) ### Dr. Nikolaus Raupp Partner ### Dr. Nikolaus RauppPartner ![](https://www.htgf.de/wp-content/uploads/2017/06/Anke-Cassing_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/anke-cassing.md) ### Dr. Anke Caßing Principal ### Dr. Anke CaßingPrincipal ![](https://www.htgf.de/wp-content/uploads/2015/10/Caroline-Fichtner_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-caroline-fichtner.md) ### Dr. Caroline Fichtner Principal ### Dr. Caroline FichtnerPrincipal ![](https://www.htgf.de/wp-content/uploads/2014/10/Kay-Balster_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/kay-g-balster.md) ### Kay G. Balster Principal ### Kay G. BalsterPrincipal ![](https://www.htgf.de/wp-content/uploads/2015/12/Frank-Hensel_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-frank-hensel-2.md) ### Dr. Frank Hensel Principal ### Dr. Frank HenselPrincipal ![](https://www.htgf.de/wp-content/uploads/2025/06/HTGF-170920252215_Webseite-864x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-joerg-traub.md) ### Dr. Jörg Traub Principal ### Dr. Jörg TraubPrincipal ![](https://www.htgf.de/wp-content/uploads/2021/09/Katharina-Severin_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/katharina-severin.md) ### Dr. Katharina Severin Senior Investment Manager ### Dr. Katharina SeverinSenior Investment Manager ![](https://www.htgf.de/wp-content/uploads/2025/12/HTGF_Juri-Bach-911x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-juri-bach-senior-investment-manager.md) ### Dr. Juri Bach Senior Investment Manager ### Dr. Juri BachSenior Investment Manager ![](https://www.htgf.de/wp-content/uploads/2022/01/Jan-Engels_666x789.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-jan-engels.md) ### Dr. Jan Engels Senior Investment Manager ### Dr. Jan EngelsSenior Investment Manager ![](https://www.htgf.de/wp-content/uploads/2023/08/HTGF-190920237376_Webseite.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-christian-kannemeier-senior-investment-manager.md) ### Dr. Christian Kannemeier Senior Investment Manager ### Dr. Christian KannemeierSenior Investment Manager ![](https://www.htgf.de/wp-content/uploads/2026/01/HTGF_Jule-Goike-912x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-jule-goike.md) ### Dr. Jule Goike Investment Manager ### Dr. Jule GoikeInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2026/02/Nicole-Moschny.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-nicole-moschny-investment-manager.md) ### Dr. Nicole Moschny Investment Manager ### Dr. Nicole MoschnyInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2024/04/HTGF-270520248026_Webseite2.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-lena-sophie-schuetter.md) ### Dr. Lena-Sophie Schütter Investment Manager ### Dr. Lena-Sophie SchütterInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2023/08/HTGF-130920235826_Webseite.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/tilmann-petersen-investment-manager.md) ### Tilmann Petersen Investment Manager ### Tilmann PetersenInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2026/05/HTGF-090620260889-864x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/dr-nikolaus-vollmer.md) ### Dr. Nikolaus Vollmer Investment Manager ### Dr. Nikolaus VollmerInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2025/03/Stefan-Ruck-Web-1000px.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/stephan-ruck-investment-manager.md) ### Dr. Stephan Ruck Investment Manager ### Dr. Stephan RuckInvestment Manager ![](https://www.htgf.de/wp-content/uploads/2025/09/HTGF-170920252522-1_Webseite.png) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/calvin-kunth.md) ### Calvin Kunth Management Associate Life Sciences & Chemistry ### Calvin KunthManagement Associate Life Sciences & Chemistry ![](https://www.htgf.de/wp-content/uploads/2026/05/Joy-Andrae_HTGF-090620261827-864x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/joy-andrae.md) ### Joy Andrä Investment Analyst ### Joy AndräInvestment Analyst ![](https://www.htgf.de/wp-content/uploads/2026/07/DSC_1552-1080x1080.jpg) [ Zum Artikel ](https://www.htgf.de/wp-content/uploads/wp-mfa-exports/manager/lea-wagner.md) ### Lea Wagner Junior Analyst ### Lea WagnerJunior Analyst [show the whole team](#) ## Added Value. _The HTGF promise_ We see the potential for real innovation before anyone else does – with a deep understanding of the market and excellent connections to research, institutes and universities. We are the door opener that your start-up needs in the financing round to revolutionise the market. We invest _first._ open/close Early-stage investments are at the heart of our business: we take early ristks on to ensure that your solution gets market ready. Bridge-building: _from science to venture._ open/close As a diverse team drawn from science, medicine and entrepreneurs, we are familiar with the challenges you face – including those that await you tomorrow. Our network is _your superpower._ open/close With our large network and over 45 companies invested in the fund, you will find the right partners to drive your business forward. 800 Ventures, _one HTGF family._ open/close Talents are your resource for success, collaborations your lever for transformation. Join the family – and grow beyond yourself. ## It**’**s you _who can change the world._ We have helped some of Germany’s most innovative companies get off the ground. We are the right partner for you, too, if… - you are R&D-based, but your business network needs to be expanded. - you have an innovative solution, technology or patent, but your lab-to-market strategy needs to be built. - your company is facing regulatory hurdles that overwhelm your team resources. - you are in an early phase and need a strong consortium for the challenging development. ### Do you want to found in ## _Life Sciences or Chemistry?_ reach out ### Is your Pitch deck ## _ready to go?_ submit now